On the basis of screening hits (1a, b), a series of selective, high affinity prostacyclin receptor antagonists was developed. The optimized lead compound 25d [(4, 5-dihydro-1H-imidazol-2- yl)-[4-(4-isopropoxybenzyl) phenyl] amine] had analgesic activity in the rat.